Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System.

Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F.

Mol Cancer Ther. 2016 Jun;15(6):1397-404. doi: 10.1158/1535-7163.MCT-15-0712. Epub 2016 May 20.

2.

BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.

Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R.

Oncotarget. 2015 Sep 29;6(29):26886-94. doi: 10.18632/oncotarget.4723.

3.

Hepatitis C virus genotype 7, a new genotype originating from central Africa.

Murphy DG, Sablon E, Chamberland J, Fournier E, Dandavino R, Tremblay CL.

J Clin Microbiol. 2015 Mar;53(3):967-72. doi: 10.1128/JCM.02831-14. Epub 2014 Dec 17.

4.

[Comparative analysis of immunoglobulin free light chains quantification by Freelite™ (The Binding Site) and N Latex FLC (Siemens) methods].

Schneider N, Wynckel A, Kolb B, Sablon E, Gillery P, Maquart FX.

Ann Biol Clin (Paris). 2013 Jan-Feb;71(1):13-9. doi: 10.1684/abc.2012.0785. French.

5.

Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment.

Niesters HG, Zoulim F, Pichoud C, Buti M, Shapiro F, D'Heuvaert N, Celis L, Doutreloigne J, Sablon E.

Antimicrob Agents Chemother. 2010 Mar;54(3):1283-9. doi: 10.1128/AAC.00970-09. Epub 2010 Jan 11.

6.

GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics.

Vanderschaeghe D, Laroy W, Sablon E, Halfon P, Van Hecke A, Delanghe J, Callewaert N.

Mol Cell Proteomics. 2009 May;8(5):986-94. doi: 10.1074/mcp.M800470-MCP200. Epub 2009 Jan 29.

7.

Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0.

Verbeeck J, Stanley MJ, Shieh J, Celis L, Huyck E, Wollants E, Morimoto J, Farrior A, Sablon E, Jankowski-Hennig M, Schaper C, Johnson P, Van Ranst M, Van Brussel M.

J Clin Microbiol. 2008 Jun;46(6):1901-6. doi: 10.1128/JCM.02390-07. Epub 2008 Apr 9.

8.

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M.

Gastroenterology. 2007 Nov;133(5):1445-51. Epub 2007 Sep 2.

PMID:
17983801
9.

Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.

Libbrecht E, Doutreloigne J, Van De Velde H, Yuen MF, Lai CL, Shapiro F, Sablon E.

J Clin Microbiol. 2007 Dec;45(12):3935-41. Epub 2007 Oct 3.

10.

The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation.

França PH, Coelho HS, Brandão CE, Segadas JA, Quintaes RF, Carrilho FJ, Ono-Nita S, Mattos AA, Tovo C, Gouvea VS, Sablon E, Vanderborght BO.

Braz J Med Biol Res. 2007 Dec;40(12):1605-14. Epub 2007 Oct 29.

11.

Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance.

Hou J, Schilling R, Janssen HL, Hansen BE, Heijtink R, Sablon E, Williams R, Lau GK, Schalm SW, Naoumov NV.

J Med Virol. 2007 Aug;79(8):1055-63.

PMID:
17596838
12.

Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.

Yuen MF, Sablon E, Libbrecht E, Van De Velde H, Wong DK, Fung J, Wong BC, Lai CL.

Antivir Ther. 2006;11(6):779-86.

PMID:
17310822
13.

Molecular analysis of hepatitis B virus isolates in Mexico: predominant circulation of hepatitis B virus genotype H.

Alvarado-Esquivel C, Sablon E, Conde-González CJ, Juárez-Figueroa L, Ruiz-Maya L, Aguilar-Benavides S.

World J Gastroenterol. 2006 Oct 28;12(40):6540-5.

14.

A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes.

Kuiken C, Combet C, Bukh J, Shin-I T, Deleage G, Mizokami M, Richardson R, Sablon E, Yusim K, Pawlotsky JM, Simmonds P; Los Alamos HIV Database Group.

Hepatology. 2006 Nov;44(5):1355-61. No abstract available.

PMID:
17058236
15.

Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B.

Yuan HJ, Ka-Ho Wong D, Doutreloigne J, Sablon E, Lai CL, Yuen MF.

J Infect. 2007 May;54(5):497-503. Epub 2006 Sep 25.

PMID:
16997379
16.

Genotyping hepatitis C viruses from Southeast Asia by a novel line probe assay that simultaneously detects core and 5' untranslated regions.

Noppornpanth S, Sablon E, De Nys K, Truong XL, Brouwer J, Van Brussel M, Smits SL, Poovorawan Y, Osterhaus AD, Haagmans BL.

J Clin Microbiol. 2006 Nov;44(11):3969-74. Epub 2006 Sep 6.

17.

Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users.

Morice Y, Cantaloube JF, Beaucourt S, Barbotte L, De Gendt S, Goncales FL, Butterworth L, Cooksley G, Gish RG, Beaugrand M, Fay F, Fay O, Gonzalez JE, Martins RM, Dhumeaux D, Vanderborght B, Stuyver L, Sablon E, de Lamballerie X, Pawlotsky JM.

J Med Virol. 2006 Oct;78(10):1296-303.

PMID:
16927280
18.

Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.

Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C, Andreone P, Lok AS.

J Clin Microbiol. 2006 Mar;44(3):1094-7.

19.

Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico.

Alvarado-Esquivel C, de la Ascensión Carrera-Gracia M, Conde-González CJ, Juárez-Figueroa L, Ruiz-Maya L, Aguilar-Benavides S, Torres-Valenzuela A, Sablon E.

J Antimicrob Chemother. 2006 Feb;57(2):221-3. Epub 2005 Dec 22.

PMID:
16373428
20.

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.

Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A.

Hepatology. 2005 Oct;42(4):962-73. Review.

PMID:
16149085
21.

Impact of precore and core promoter mutations on hepatic histology in patients with chronic hepatitis B.

Yuan HJ, Yuen MF, Ka-Ho Wong D, Sum SM, Sablon E, Ng IO, Lai CL.

Aliment Pharmacol Ther. 2005 Aug 15;22(4):301-7.

22.

Hepatitis virus and HIV infections in inmates of a state correctional facility in Mexico.

Alvarado-Esquivel C, Sablon E, Martínez-García S, Estrada-Martínez S.

Epidemiol Infect. 2005 Aug;133(4):679-85.

23.

The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B.

Yuan HJ, Yuen MF, Ka-Ho Wong D, Sablon E, Lai CL.

J Viral Hepat. 2005 Jul;12(4):373-9.

PMID:
15985007
24.

Advances in Molecular Diagnosis of HBV Infection and Drug Resistance.

Sablon E, Shapiro F.

Int J Med Sci. 2005;2(1):8-16. Epub 2005 Jan 5.

25.

Metabolic engineering of Escherichia coli: construction and characterization of a gltA (citrate synthase) knockout mutant.

Vandedrinck S, Deschamps G, Sablon E, Vandamme EJ.

Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet. 2001;66(3a):333-6.

PMID:
15954614
26.

Construction and characterization of a PPC (phosphoenolpyruvate carboxylase) knockout mutant of Escherichia coli.

Vandedrinck S, Deschamps G, Sablon E, Vandamme EJ.

Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet. 2001;66(4):345-9. No abstract available.

PMID:
15954317
27.

Determinants for the occurrence of acute exacerbation of hepatitis B virus infection in Chinese patients after HBeAg seroclearance.

Yuan HJ, Yuen MF, Wong DK, Sum SM, Doutreloigne J, Sablon E, Lai CL.

J Clin Microbiol. 2005 Apr;43(4):1594-9.

28.

Hepatitis B virus genotypes and precore mutations in Scottish blood donors.

Davidson F, Lycett C, Sablon E, Petrik J, Dow BC.

Vox Sang. 2005 Feb;88(2):87-92.

PMID:
15720605
29.

Strong association between genotype F and hepatitis B virus (HBV) e antigen-negative variants among HBV-infected argentinean blood donors.

França PH, González JE, Munné MS, Brandão LH, Gouvea VS, Sablon E, Vanderborght BO.

J Clin Microbiol. 2004 Nov;42(11):5015-21.

30.

High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users.

Chen BF, Chen PJ, Jow GM, Sablon E, Liu CJ, Chen DS, Kao JH.

J Med Virol. 2004 Dec;74(4):536-42.

PMID:
15484267
31.
32.

Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.

Vuillermoz I, Khattab E, Sablon E, Ottevaere I, Durantel D, Vieux C, Trepo C, Zoulim F.

J Med Virol. 2004 Sep;74(1):41-53.

PMID:
15258967
33.

Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong.

Yuen MF, Sablon E, Tanaka Y, Kato T, Mizokami M, Doutreloigne J, Yuan HJ, Wong DK, Sum SM, Lai CL.

J Hepatol. 2004 Jul;41(1):119-25.

PMID:
15246217
34.

HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.

Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL.

Hepatology. 2004 Jun;39(6):1694-701. Erratum in: Hepatology. 2004 Sep;40(3):767.

PMID:
15185311
35.

Hepatitis B viral genotyping with the research INNO-LiPA HBV genotyping line probe assay.

De Gendt S, Shapiro F, Juras J, Van Assche E, Maertens G, Sablon E.

Methods Mol Med. 2004;95:175-86. No abstract available.

PMID:
14982057
36.

Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine.

Yuen MF, Wong DK, Sablon E, Yuan HJ, Sum SM, Hui CK, Chan AO, Wang BC, Lai CL.

Antivir Ther. 2003 Dec;8(6):531-4.

PMID:
14760886
37.

Hepatitis B virus genotype A and D and clinical outcomes of liver transplantation for HBV-related disease.

Girlanda R, Mohsen AH, Smith H, Sablon E, Yuen MF, O'Grady J, Muiesan P, Rela M, Heaton N, Norris S.

Liver Transpl. 2004 Jan;10(1):58-64.

38.

Evaluation of a line probe assay for identification of hepatitis B virus precore variants in serum from chronic hepatitis B carriers.

Cameron-Wilson CL, Muir P, Ballard AL, Corden S, Boxall EH, Sablon E, Stuyver L.

J Virol Methods. 2003 Dec;114(1):97-103.

PMID:
14599684
39.

Early detection of hepatitis B drug resistance: implications for patient management.

Sablon E, Shapiro F, Zoulim F.

Expert Rev Mol Diagn. 2003 Sep;3(5):535-47. Review.

PMID:
14510175
40.

Successful HCV genotyping of previously failed and low viral load specimens using an HCV RNA qualitative assay based on transcription-mediated amplification in conjunction with the line probe assay.

Comanor L, Elkin C, Leung K, Krajden M, Kronquist K, Nicolas K, Horansky E, deMedina M, Kittichai P, Sablon E, Ziermann R, Sherlock C.

J Clin Virol. 2003 Sep;28(1):14-26.

PMID:
12927747
41.

Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation.

Yuen MF, Sablon E, Wong DK, Yuan HJ, Wong BC, Chan AO, Lai CL.

Clin Infect Dis. 2003 Aug 15;37(4):593-7. Epub 2003 Jul 29. Erratum in: Clin Infect Dis. 2004 Apr 1;38(7)1046.

PMID:
12905145
42.
43.

Prognostic factors in severe exacerbation of chronic hepatitis B.

Yuen MF, Sablon E, Hui CK, Li TM, Yuan HJ, Wong DK, Doutreloigne J, Bogaerts V, Wong BC, Fan ST, Lai CL.

Clin Infect Dis. 2003 Apr 15;36(8):979-84. Epub 2003 Apr 2.

PMID:
12684909
44.

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

Lampertico P, Del Ninno E, Viganò M, Romeo R, Donato MF, Sablon E, Morabito A, Colombo M.

Hepatology. 2003 Apr;37(4):756-63.

PMID:
12668967
45.

Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1.

Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL.

J Infect Dis. 2003 Apr 1;187(7):1071-4. Epub 2003 Mar 7.

PMID:
12660921
46.

Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma.

Yuen MF, Sablon E, Yuan HJ, Wong DK, Hui CK, Wong BC, Chan AO, Lai CL.

Hepatology. 2003 Mar;37(3):562-7.

PMID:
12601354
47.

Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus.

Yuen MF, Sablon E, Yuan HJ, Hui CK, Wong DK, Doutreloigne J, Wong BC, Chan AO, Lai CL.

J Infect Dis. 2002 Nov 1;186(9):1335-8. Epub 2002 Oct 11.

PMID:
12402204
48.

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.

Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K, Sablon E.

J Clin Microbiol. 2002 Oct;40(10):3729-34.

49.

Comparative study of two anti-HCV screening tests in a large genotyped population of Brazilian dialysis patients.

Bassit L, Van Heuverswyn H, De Bosschere K, Nishiya AS, Carrilho FJ, Moraes CR, Sablon E.

Eur J Clin Microbiol Infect Dis. 2002 May;21(5):404-6. Epub 2002 May 7. No abstract available.

PMID:
12072929
50.

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL.

Hepatology. 2001 Oct;34(4 Pt 1):785-91.

PMID:
11584376

Supplemental Content

Loading ...
Support Center